Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
322 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 11 Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 12 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 13 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 18 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 22 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 27 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 28 A. Menarini Industrie Farmaceutiche Riunite Srl 28 Adamis Pharmaceuticals Corporation 29 Aeterna Zentaris Inc. 30 Alethia Biotherapeutics Inc. 31 Amgen Inc. 32 AnGes MG, Inc. 33 Aphios Corporation 34 Armour Therapeutics Inc. 35 Arno Therapeutics, Inc. 36 Astellas Pharma Inc. 37 Astex Pharmaceuticals, Inc. 38 AstraZeneca PLC 39 Ausio Pharmaceuticals, LLC 40 Bavarian Nordic A/S 41 Bayer AG 42 Beta Pharma, Inc. 43 Bio-Cancer Treatment International Limited 44 Biscayne Pharmaceuticals, Inc. 45 Boehringer Ingelheim GmbH 46 Celldex Therapeutics, Inc. 47 Corcept Therapeutics Incorporated 48 CureTech Ltd. 49 CytoVac A/S 50 DexTech Medical AB 51 Enceladus Pharmaceuticals BV 52 Endo Pharmaceuticals Inc. 53 EndoCeutics, Inc. 54 Endocyte, Inc. 55 Errant Gene Therapeutics, LLC 56 Fujifilm Corporation 57 Genentech, Inc. 58 Glactone Pharma AB 59 GlaxoSmithKline plc 60 GTx, Inc. 61 Harbor Therapeutics, Inc. 62 Hybrigenics S.A. 63 Incuron, LLC 64 Io Therapeutics, Inc. 65 Isis Pharmaceuticals, Inc. 66 Johnson & Johnson 67 Kinex Pharmaceuticals, LLC 68 Mediolanum farmaceutici S.p.A. 69 Medivation, Inc. 70 Merck KGaA 71 NewLink Genetics Corporation 72 Novartis AG 73 Oncogenex Pharmaceuticals, Inc. 74 Orion Oyj 75 Orphagen Pharmaceuticals, Inc. 76 Oxford BioMedica plc 77 Panacela Labs, Inc. 78 Takeda Oncology 79 Tokai Pharmaceuticals, Inc. 80 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 81 Assessment by Monotherapy Products 81 Assessment by Target 82 Assessment by Mechanism of Action 86 Assessment by Route of Administration 89 Assessment by Molecule Type 91 Drug Profiles 93 AB-3A4 - Drug Profile 93 afatinib - Drug Profile 94 AKAGU-52 - Drug Profile 98 Alecsat - Drug Profile 99 alisertib - Drug Profile 101 AM-0010 - Drug Profile 105 AMPI-109 - Drug Profile 106 apatorsen - Drug Profile 107 APH-0701 - Drug Profile 109 AT-001 - Drug Profile 110 AUS-131 - Drug Profile 111 AZD-3965 - Drug Profile 113 AZD-8186 - Drug Profile 115 BAY-1024767 - Drug Profile 116 BCT-100 - Drug Profile 117 BIS-1602 - Drug Profile 119 BPI-5143 - Drug Profile 120 buparlisib hydrochloride - Drug Profile 121 CG-1521 - Drug Profile 125 CIM-1 - Drug Profile 126 Dendritic Cell Therapy to Target Mucin 1 for Prostatic Adenocarcinoma - Drug Profile 127 dexamethasone acetate - Drug Profile 128 EC-1169 - Drug Profile 129 EM-5854 - Drug Profile 130 EN-3356 - Drug Profile 131 enzalutamide - Drug Profile 133 EPI-001 - Drug Profile 136 galeterone - Drug Profile 137 GEN-0101 - Drug Profile 139 GPA-500 - Drug Profile 141 GPA-512 - Drug Profile 142 GPB-600 - Drug Profile 143 GSK-2849330 - Drug Profile 144 GTx-758 - Drug Profile 145 GX-301 - Drug Profile 147 HE-3235 - Drug Profile 148 HyperAcute Vaccine for Prostate Cancer - Drug Profile 150 inecalcitol - Drug Profile 151 ipatasertib - Drug Profile 153 IRX-4204 - Drug Profile 155 ISIS-EIF4ERx - Drug Profile 157 ITK-1 - Drug Profile 159 JNJ-56021927 - Drug Profile 161 KRM-20 - Drug Profile 163 KX-01 - Drug Profile 164 LFA-102 - Drug Profile 166 mepacrine - Drug Profile 168 MIA-602 - Drug Profile 170 mifepristone - Drug Profile 171 MSB-0010718C - Drug Profile 174 MVA-BN-PRO - Drug Profile 175 MVI-118 - Drug Profile 176 ODM-201 - Drug Profile 177 onalespib - Drug Profile 179 onapristone ER - Drug Profile 182 Oncolytic Virus for Oncology - Drug Profile 184 ozarelix - Drug Profile 185 pasireotide LAR - Drug Profile 187 pasotuxizumab - Drug Profile 189 Peptide for Androgen-Independent Prostate Cancer - Drug Profile 191 pidilizumab - Drug Profile 192 radium Ra 223 dichloride - Drug Profile 194 ribociclib - Drug Profile 197 rilotumumab - Drug Profile 200 sabarubicin - Drug Profile 202 Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer - Drug Profile 204 Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer - Drug Profile 205 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 206 Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 207 solitomab - Drug Profile 208 Somadex - Drug Profile 210 SR-16388 - Drug Profile 211 TeloB-VAX - Drug Profile 213 TroVax - Drug Profile 214 vandetanib - Drug Profile 217 varlilumab - Drug Profile 223 VT-464 - Drug Profile 225 zoptarelin doxorubicin - Drug Profile 226 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 228 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 297 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 303 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 305 Featured News & Press Releases 305 Appendix 315 Methodology 315 Coverage 315 Secondary Research 315 Primary Research 315 Expert Panel Validation 315 Contact Us 315 Disclaimer 316
List of Tables Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17 Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2015 18 Number of Products under Development by Companies, H1 2015 20 Number of Products under Development by Companies, H1 2015 (Contd..1) 21 Number of Products under Development by Companies, H1 2015 (Contd..2) 22 Number of Products under Development by Companies, H1 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2015 24 Comparative Analysis by Late Stage Development, H1 2015 25 Comparative Analysis by Clinical Stage Development, H1 2015 26 Comparative Analysis by Early Stage Development, H1 2015 27 Products under Development by Companies, H1 2015 28 Products under Development by Companies, H1 2015 (Contd..1) 29 Products under Development by Companies, H1 2015 (Contd..2) 30 Products under Development by Companies, H1 2015 (Contd..3) 31 Products under Development by Companies, H1 2015 (Contd..4) 32 Products under Investigation by Universities/Institutes, H1 2015 33 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 34 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 35 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 36 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 37 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H1 2015 38 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H1 2015 39 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H1 2015 40 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2015 41 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H1 2015 42 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2015 43 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 44 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2015 45 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 46 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2015 47 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H1 2015 48 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Beta Pharma, Inc., H1 2015 49 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2015 50 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 51 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 52 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 53 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 54 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureTech Ltd., H1 2015 55 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H1 2015 56 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2015 57 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2015 58 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H1 2015 59 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by EndoCeutics, Inc., H1 2015 60 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H1 2015 61 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H1 2015 62 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H1 2015 63 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2015 64 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2015 65 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 66 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2015 67 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H1 2015 68 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H1 2015 69 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Incuron, LLC, H1 2015 70 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H1 2015 71 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 72 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H1 2015 73 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 74 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Mediolanum farmaceutici S.p.A., H1 2015 75 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2015 76 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H1 2015 77 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 78 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2015 79 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 80 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H1 2015 81 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 82 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oxford BioMedica plc, H1 2015 83 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Panacela Labs, Inc., H1 2015 84 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Oncology, H1 2015 85 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H1 2015 86 Assessment by Monotherapy Products, H1 2015 87 Number of Products by Stage and Target, H1 2015 89 Number of Products by Stage and Mechanism of Action, H1 2015 93 Number of Products by Stage and Route of Administration, H1 2015 96 Number of Products by Stage and Molecule Type, H1 2015 98 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2015 234 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2015 303 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H1 2015 304 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H1 2015 305 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H1 2015 306 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H1 2015 307 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..5), H1 2015 308 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2015 309 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H1 2015 310
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
